Imeliza Avigliano
Family Medicine · Hockessin, DENPI 1215013347
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,431 and has fallen 80.4% since, to $280 in 2025.
Across 220 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$720
- Abbott$467
- Lilly USA, LLC$455
- Astellas Pharma US Inc$365
- AstraZeneca$306
- GSK$298
- plus $1K from 13 others
What the payments were for
- Food & beverage$3,80096%
- Education$1564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $720 |
| Abbott | 16 | $467 |
| Lilly USA, LLC | 23 | $455 |
| Astellas Pharma US Inc | 22 | $365 |
| AstraZeneca | 14 | $306 |
| GSK | 17 | $298 |
| Novo Nordisk | 17 | $294 |
| Boehringer Ingelheim | 14 | $283 |
| Pfizer | 11 | $240 |
| Sanofi-aventis U.S. LLC | 8 | $142 |
| Idorsia Pharmaceuticals US Inc | 5 | $81 |
| Corium, LLC | 3 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Exact Sciences | 2 | $39 |
| Amgen | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,956 in reported general payments places this provider in the 85th percentile of 352 family medicine providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $65,071 |
| FarxigaDapagliflozin Propanediol | 26 | $35,558 |
| JardianceEmpagliflozin | 21 | $25,304 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $20,737 |
| MounjaroTirzepatide | 21 | $20,734 |
| VivitrolNaltrexone Microspheres | 13 | $19,987 |
| SynjardyEmpagliflozin/Metformin Hcl | 16 | $9,620 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,041 |
| Rosuvastatin Calcium | 140 | $2,566 |
| Atorvastatin Calcium | 187 | $1,959 |
| Bupropion XlBupropion Hcl | 60 | $1,781 |
| Levothyroxine Sodium | 150 | $1,528 |
| SynthroidLevothyroxine Sodium | 35 | $1,454 |
| Omeprazole | 105 | $1,394 |
| Escitalopram Oxalate | 61 | $1,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $294 | $65,07150 claims |
| AstraZenecaFarxiga | $306 | $35,55826 claims |
| Boehringer IngelheimJardiance, Synjardy | $283 | $34,92437 claims |
| GSKTrelegy Ellipta | $298 | $20,73727 claims |
| Lilly USA, LLCMounjaro | $455 | $20,73421 claims |
| AbbVieSynthroid | $720 | $1,45435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 352 family medicine providers in Delaware.
Other family medicine in Hockessin
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Wayne TuckerBear$20K
- Ian MyersNewark$17K
- Glenn HamiltonWilmington$17K
- Dustin DavisGeorgetown$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.